＜Research＞UBS Raises HANSOH PHARMA (03692.HK) TP to $20.8, Rating Buy as Sector Top Pick

　　UBS released a research report believing that HANSOH PHARMA (03692.HK) -0.440 (-2.475%) Short selling $19.35M; Ratio 36.487% 's high quality drug pipeline is undervalued. Therefore, the broker raised its target price from $17.8 to $20.8, with rating reiterated at Buy as its sector top pick.

　　UBS analyzed in depth its key mid- and late-stage drug production line and came up with unadjusted peak sales of RMB11.2 billion and a blended probability of success (PoS) of 61.1%. All else being equal, the current share price only considers a 2.2% blended PoS.

　　Related NewsCICC: Re-entry Into High Div. Theme Should Wait Until Sufficient Pullback; Prefers Semiconductors/ Autos/ Medias/ Softwares/ Biotechs in Short Term

　　In addition, UBS believed that HANSOH PHARMA has the potential to unlock the overseas value of its pipeline through a license deal, bringing further upside to the underlying valuation.

　　(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-07-22 16:25.)

　　AAStocks Financial News